Novavax Reschedules 4th Annual Investor and Analyst Meeting
October 07 2016 - 8:00AM
Novavax, Inc., (Nasdaq:NVAX) today announced it has rescheduled its
4th annual Investor and Analyst Meeting. The Company will host an
Investor and Analyst update as part of its third quarter financial
results conference call and webcast on Wednesday, November 9, 2016.
“We continue to analyze data from our Resolve
clinical trial and map out the clinical path forward for our older
adult RSV F Vaccine in the context of our other clinical programs,”
said Stanley C. Erck, President and CEO. “We would like to finalize
those plans and communicate them at the same time as our third
quarter financial results call in early November. We look forward
to providing the next steps in our RSV F Vaccine program, as well
as an update on the path forward for additional programs in our
pipeline and our financial and operating plan, which we will
provide as a dedicated part of our November financial results.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
vaccine company committed to delivering novel products to prevent a
broad range of infectious diseases. Our recombinant nanoparticles
and Matrix-M™ adjuvant technology are the foundation for
groundbreaking innovation that improves global health through safe
and effective vaccines. Additional information about Novavax is
available on the company’s website, novavax.com.
Forward-Looking Statements
Statements herein relating to the future of
Novavax and the ongoing development of its vaccine and adjuvant
products are forward-looking statements. Novavax cautions that
these forward looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include those identified under the
heading “Risk Factors” in the Novavax Annual Report on Form 10-K
for the year ended December 31, 2015 as filed with the Securities
and Exchange Commission (SEC). We caution investors not to place
considerable reliance on the forward-looking statements contained
in this press release. You are encouraged to read our filings with
the SEC, available at sec.gov, for a discussion of these and other
risks and uncertainties. The forward-looking statements in this
press release speak only as of the date of this document, and we
undertake no obligation to update or revise any of the statements.
Our business is subject to substantial risks and uncertainties,
including those referenced above. Investors, potential investors,
and others should give careful consideration to these risks and
uncertainties.
Contact: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
ir@novavax.com
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024